Bitwise Crypto Industry Innovators ETF vs Neurocrine Biosciences Inc — how do they compare? Bitwise Crypto Industry Innovators ETF trades at $22.69, while Neurocrine Biosciences Inc trades at $156.68 (market cap $16.46B). The key difference: Neurocrine Biosciences Inc is trading nearer its 52-week high, Bitwise Crypto Industry Innovators ETF nearer its low. Which is the better fit depends on your goals.
| BITQ | NBIX | |
|---|---|---|
Sector | Crypto-linked | Health |
52-Week High | $30.43 | $185.50 |
52-Week Low | $16.74 | $123.10 |
Market Cap | — | $16.46B |
Enterprise Value | — | $16.48B |
Signals from Pluang's Aura AI — not financial advice
BITQ trades at $22.69, up 2.25% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The stock lacks disclosed financial ratios, limiting fundamental analysis. Recent news highlights institutional interest in crypto ETFs, though BITQ itself is a US stock with no direct crypto operations.
The outlook remains cautious due to weak technicals and absent fundamentals. Risks include market volatility and unverified financial health. Analyst consensus is unavailable, requiring deeper research into company filings for investment clarity.
Neurocrine Biosciences (NBIX) trades at $156.95, down 4.83% in the last session, with a bearish technical signal from moving averages and ADX. The stock shows strong fundamentals, including a 39% year-over-year revenue growth in Q2 2026 to $959 million and a net income margin of 20.91% for 2026. Recent developments include positive INGREZZA clinical data and the initiation of a Phase 1 study for a GLP-1/GIP/glucagon receptor triple agonist, though safety concerns were raised for Vykat XR in Prader-Willi Syndrome.
The outlook for NBIX is positive with a consensus price target of $208.82, implying 33% upside, supported by robust earnings beats and portfolio expansion. Risks include drug safety issues, competitive pressures, and reliance on INGREZZA sales. Investors should weigh strong analyst bullishness against regulatory and execution risks in the biopharmaceutical sector.
Trailing returns across standard periods
Latest headlines on both assets
BITQ tracks companies at the forefront of the crypto economy, including miners, equipment suppliers, and financial service providers. It offers indirect exposure to the growth of the broader crypto ecosystem.
Read more on BITQ →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →